ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2020
SARS-CoV-2 asymptomatic infection in a patient under treatment with dupilumab.
Article in Journal of the European Academy of Dermatology and Venereology : JEADV, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.Dermatologic therapy · 2022Pooled it
- Clinical and Immunological Factors That Distinguish COVID-19 From Pandemic Influenza A(H1N1).Frontiers in immunology · 2021Trial
- Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2022Article
- Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.Immunologic research · 2022Article
- COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.The journal of allergy and clinical immunology. In practice · 2022Article
- The Use of Biologics During the COVID-19 Pandemic.Dermatologic clinics · 2021Review
- Dermatological aspects of SARS-CoV-2 infection: mechanisms and manifestations.Archives of dermatological research · 2021Review
- Article
- Zoonotic coronavirus epidemics: Severe acute respiratory syndrome, Middle East respiratory syndrome, and coronavirus disease 2019.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2021Review
- Association of COVID-19 with skin diseases and relevant biologics: a cross-sectional study using nationwide claim data in South Korea.The British journal of dermatology · 2021Article
- COVID-19 in Immunocompromised Hosts: What We Know So Far.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Review
- COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review.Clinical, cosmetic and investigational dermatology · 2021Article
- Impact of Anti-Type 2 Inflammation Biologic Therapy on COVID-19 Clinical Course and Outcome.Journal of inflammation research · 2021Review
- Dupilumab in atopic dermatitis, a protocol for SARS-COV-2-infected patients.Dermatologic therapy · 2020Article
- Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration.International journal of dermatology · 2020Review
- Impact of COVID-19 on patients with atopic dermatitis.Clinics in dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.